Phenotype and genotype in 52 patients with Rubinstein–Taybi syndrome caused by <i>EP300</i> mutations

  • Patricia Fergelot
    Department of Genetics, and INSERM U1211 University Hospital of Bordeaux Bordeaux France
  • Martine Van Belzen
    Department of Clinical Genetics Leiden University Medical Center Leiden The Netherlands
  • Julien Van Gils
    Department of Genetics University Hospital Center Bordeaux France
  • Alexandra Afenjar
    Unité de Génétique Hospital Armand Trousseau‐La Roche‐Guyon AP‐HP Paris France
  • Christine M. Armour
    Regional Genetics Unit Children's Hospital of Eastern Ontario Ottawa Canada
  • Benoit Arveiler
    Department of Genetics, and INSERM U1211 University Hospital of Bordeaux Bordeaux France
  • Lex Beets
    Department of Pediatrics Academic Medical Center Amsterdam The Netherlands
  • Lydie Burglen
    Unité de Génétique Hospital Armand Trousseau‐La Roche‐Guyon AP‐HP Paris France
  • Tiffany Busa
    Unité de Génétique Clinique Hospital La Timone AP‐HM Marseille France
  • Marie Collet
    Département de Génétique Hospital Necker‐Enfants Malades AP‐HP Paris France
  • Julie Deforges
    Department of Genetics University Hospital Center Bordeaux France
  • Bert B. A. de Vries
    Department of Human Genetics, Donders Centre for Neuroscience Radboud University Medical Center Nijmegen The Netherlands
  • Elena Dominguez Garrido
    Center for Biomedical Research Logrono‐La Rioja Spain
  • Nathalie Dorison
    Departement de Neuropédiatrie Institut Jérôme Lejeune Paris France
  • Juliette Dupont
    Serviço de Genética Departamento de Pediatria Hospital de Santa Maria CHLN Lisboa Portugal
  • Christine Francannet
    Service de Génétique Médicale CHU Estaing Clermont‐Ferrand France
  • Sixto Garciá‐Minaúr
    Institute of Medical and Molecular Genetics University Hospital La Paz Madrid Spain
  • Elisabeth Gabau Vila
    Genetics Clinic Hospital de Sabadell Corporació Sanitària Parc Taulí Sabadell Spain
  • Samuel Gebre‐Medhin
    Division of Clinical Genetics Department of Laboratory Medicine Lund University Lund Sweden
  • Blanca Gener Querol
    Hospital de Cruces Baracaldo Spain
  • David Geneviève
    Service de Génétique Médicale Hospital Arnaud de Villeneuve CHU Montpellier Montpellier France
  • Marion Gérard
    Service de Génétique Hospital Clémenceau CHU de Caen, Caen France
  • Cristina Giovanna Gervasini
    Department of Medical Genetics University of Milan Milan Italy
  • Alice Goldenberg
    Unité de Génétique Clinique Hospital Charles Nicolle CHU Rouen, Rouen France
  • Dragana Josifova
    Department of Medical Genetics Guy's and St Thomas Hospital London United Kingdom
  • Katherine Lachlan
    Wessex Clinical Genetics Service Princess Anne Hospital Southampton United Kingdom
  • Saskia Maas
    Department of Pediatrics Academic Medical Center Amsterdam The Netherlands
  • Bruno Maranda
    Laboratoire de Médecine Génétique CHUQ Pavillon CHUL Saint Foy Canada
  • Jukka S. Moilanen
    PEDEGO Research Unit, and Medical Research Center Oulu Department of Clinical Genetics University of Oulu Oulu University Hospital Oulu Finland
  • Ann Nordgren
    Department of Molecular Medicine and Surgery, and Center for Molecular Medicine Karolinska University Hospital Stockholm Sweden
  • Philippe Parent
    Département de Pédiatrie et Génétique Médicale Hospital Augustin Morvan CHU Brest Brest France
  • Julia Rankin
    Department of Clinical Genetics Royal Devon and Exeter NHS Foundation Trust Exeter United Kingdom
  • Willie Reardon
    Our Lady's Hospital for Sick Children Crumlin Ireland
  • Marlène Rio
    Unité de Génétique Clinique Hospital La Timone AP‐HM Marseille France
  • Joëlle Roume
    Unité de Génétique Médicale CHI Poissy Saint Germain en Laye France
  • Adam Shaw
    Department of Medical Genetics Guy's and St Thomas Hospital London United Kingdom
  • Robert Smigiel
    Department of Paediatrics Wroclaw Medical University Wroclaw Poland
  • Amaia Sojo
    Hospital de Cruces Baracaldo Spain
  • Benjamin Solomon
    Division of Medical Genomics Inova Translational Medical Institute Falls Church
  • Agnieszka Stembalska
    Department of Genetics Wroclaw Medical University Wroclaw Poland
  • Constance Stumpel
    Department of Clinical Genetics and School for Oncology and Developmental Biology Maastricht University Medical Center Maastricht The Netherlands
  • Francisco Suarez
    Service de Génétique Hospital Virgen de la Salud Toledo Spain
  • Paulien Terhal
    Department of Medical Genetics University Medical Centre Utrecht Utrecht The Netherlands
  • Simon Thomas
    Wessex Regional Genetics Laboratory Salisbury District Hospital Salisbury United Kingdom
  • Renaud Touraine
    Service de Génétique Clinique et Moléculaire CHU Hôpital‐Nord Saint‐Etienne France
  • Alain Verloes
    Département de Génétique CHU Robert Debré AP‐HP Paris France
  • Catherine Vincent‐Delorme
    Service de Génétique Médicale Hospital d'Arras CHU de Lille Arras France
  • Josephine Wincent
    Department of Molecular Medicine and Surgery, and Center for Molecular Medicine Karolinska University Hospital Stockholm Sweden
  • Dorien J. M. Peters
    Department of Clinical Genetics Leiden University Medical Center Leiden The Netherlands
  • Oliver Bartsch
    Institute of Human Genetics University Medical Centre Mainz Germany
  • Lidia Larizza
    Department of Health Sciences University of Milan Milan Italy
  • Didier Lacombe
    Department of Genetics, and INSERM U1211 University Hospital of Bordeaux Bordeaux France
  • Raoul C. Hennekam
    Department of Pediatrics Academic Medical Center Amsterdam The Netherlands

説明

<jats:sec><jats:label /><jats:p>Rubinstein–Taybi syndrome (RSTS) is a developmental disorder characterized by a typical face and distal limbs abnormalities, intellectual disability, and a vast number of other features. Two genes are known to cause RSTS, <jats:italic>CREBBP</jats:italic> in 60% and <jats:italic>EP300</jats:italic> in 8–10% of clinically diagnosed cases. Both paralogs act in chromatin remodeling and encode for transcriptional co‐activators interacting with >400 proteins. Up to now 26 individuals with an <jats:italic>EP300</jats:italic> mutation have been published. Here, we describe the phenotype and genotype of 42 unpublished RSTS patients carrying <jats:italic>EP300</jats:italic> mutations and intragenic deletions and offer an update on another 10 patients. We compare the data to 308 individuals with <jats:italic>CREBBP</jats:italic> mutations. We demonstrate that <jats:italic>EP300</jats:italic> mutations cause a phenotype that typically resembles the classical RSTS phenotype due to <jats:italic>CREBBP</jats:italic> mutations to a great extent, although most facial signs are less marked with the exception of a low‐hanging columella. The limb anomalies are more similar to those in <jats:italic>CREBBP</jats:italic> mutated individuals except for angulation of thumbs and halluces which is very uncommon in <jats:italic>EP300</jats:italic> mutated individuals. The intellectual disability is variable but typically less marked whereas the microcephaly is more common. All types of mutations occur but truncating mutations and small rearrangements are most common (86%). Missense mutations in the HAT domain are associated with a classical RSTS phenotype but otherwise no genotype–phenotype correlation is detected. Pre‐eclampsia occurs in 12/52 mothers of <jats:italic>EP300</jats:italic> mutated individuals versus in 2/59 mothers of CREBBP mutated individuals, making pregnancy with an <jats:italic>EP300</jats:italic> mutated fetus the strongest known predictor for pre‐eclampsia. © 2016 Wiley Periodicals, Inc.</jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ